Table 2.

Common toxicities reported in the LUX-Lung trials

Trial	Incidence of toxicity associated with afatinib
LUX-Lung136	• Diarrhea: 87% (17% were grade 3) • Acneiform rash: 78% (14% were grade 3) • Possible treatment-related death: 2 patients
LUX-Lung 231	• Diarrhea grade 3: 22% in 50 mg/day group and 7% in 40 mg/day group • Rash/acne grade 3: 28% in 50 mg/day group and 7% in 40 mg/day group
LUX-Lung 38	• Diarrhea: 95.2% of patients (14.4% had grade 3) • Rash: 89.1% of patients (16.2% had grade 3) • Mucositis: 72.1% (8.7% had grade 3 and 0.4% had grade 4) • Paronychia: 56.8% (11.4% had grade 3) • Deaths: 4 patients
LUX-Lung 437	• Diarrhea: 100% • Rash/acne: 91.9% • Discontinuation of afatinib due to side effects: 29%
LUX-Lung 544	• Diarrhea: 53.8% • Alopecia: 32.6% • Asthenia: 27.3%
LUX-Lung 633	• Rash/acne: 14.6% • Diarrhea: 5.4% • Stomatitis/mucositis: 5.4% • Treatment-related serious adverse events: 6.3%
LUX-Lung 7	• Ongoing ClinicalTrials.gov identifier: NCT01466660
LUX-Lung 831	• Diarrhea: 9.7% (≥ grade 3) • Rash/acne: 5.5% (grade 3) • Stomatitis: 3.3% (grade 3)